NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

The ECA was the only choice they had when they tossed out PFS primary endpoint. But ECA Guidance requires they are designed BEFORE the trial starts when the FDA approves the protocol. That CERTAINLY didn't happen in NWBO's P3 trial.

UCLA is running a study with PLACEBO.

And guess what Dr, Liau chose for the efficacy endpoint from the clinicaltrials.gov protocol:
"Secondary Outcome Measures :
6 month progression-free survival (PFS6) [Time Frame: At 6 months] "

But yet she claimed that PFS was inappropriate for DCVax-L -- guess she changed her mind.